Sichuan Cancer Hospital and Research Institute
Sichuan Cancer Hospital and Research Institute
Chengdu, Sichuan, China7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Not applicable | 2026-10-06 | NCT06524427 | |
| Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Not applicable | 2026-07-14 | NCT06577792 | |
| Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC | Chemoembolization, Therapeutic; Chemotherapy; Conversion Therapy; Tislelizumab; Unresectable Stage III Non-small Cell Lung Cancer | Not yet recruiting | Phase 2 | 2026-05-01 | NCT07561983 | |
| TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma | Apatinib; Camrelizumab; Transarterial Chemoembolization; Unresectable Hepatocellular Carcinoma | Recruiting | Phase 3 | 2026-04-14 | NCT06485466 | |
| Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Active, not recruiting | Phase 2 | 2025-11-20 | NCT05189730 | |
| A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma | Lung Metastatic Nasopharyngeal Carcinoma | Not yet recruiting | Not applicable | 2025-07-14 | NCT07062484 | |
| Sintilimab Plus NCT or NCRT Versus NCRT for ESCC | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Not yet recruiting | Phase 3 | 2022-10-25 | NCT05244798 |